Bandhan Healthcare Fund
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.
Growthvine rating: 1/5 — ranked #82 of 84 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹11.17 (as of 2026-08-21) |
|---|
| AUM | ₹319 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Viraj Kulkarni |
|---|
| Exit load | 0.5% for redemption within 30 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -8.92% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 102.3% of NIFTY Pharma's upside and 154.7% of its downside.
Market cap allocation
| Large cap | 36.0% |
|---|
| Mid cap | 31.2% |
|---|
| Small cap | 32.8% |
|---|
Concentration
| Top 5 holdings | 34.8% |
|---|
| Top 10 holdings | 52.9% |
|---|
| Total holdings | 34 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 10.9%
- Apollo Hospitals Enterprises Ltd. — 8.4%
- Cipla Ltd. — 6.9%
- Torrent Pharmaceuticals Ltd. — 4.5%
- Divis Laboratories Ltd. — 4.0%
- Triparty Repo TRP_030826 — 4.0%
- Aurobindo Pharma Ltd. — 4.0%
- Global Health Limited — 3.6%
- Dr. Reddys Laboratories Ltd. — 3.6%
- Glenmark Pharmaceuticals ltd — 3.5%
Top sectors
- Pharma & Biotech — 67.1%
- Healthcare — 28.4%
- Miscellaneous — 1.0%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 14.2% | Q1 (Top) | #17 of 76 |